

June 22, 2010

ATTN: Medical Health Officers and Branch Offices

Public Health Nursing Administrators and Assistant Administrators

Holders of Communicable Disease Control Manuals

Re: Influenza A (H1N1) 2009 Pandemic Monovalent Vaccine (Without

Adjuvant) {A/California/7/2009 (H1N1)v-like virus}

Currently, the epidemiologic profile of pandemic H1N1 activity in Canada is of very low activity without sustained transmission and at most sporadic detections for some time. While pandemic H1N1 detection also remains sporadic in the southern hemisphere to date, their 2010 influenza season is still underway and typically spans April to September.

For the above reasons, it is recommended that BC's remaining stock of unadjuvanted influenza A (H1N1) pandemic monovalent vaccine be considered only for people who have not yet received pandemic vaccine and may be travelling to the southern hemisphere or those otherwise at recognized ongoing risk of exposure (i.e. laboratory workers who request it). This recommendation covers the time period from the present until the 2010/11 seasonal influenza vaccine program begins or the epidemiologic profile changes and revised recommendations are issued. It is consistent with recent guidelines issued also by the Public Health Agency of Canada.

Administrative Circular 2010:10



There are two differences from the recommendations for seasonal influenza vaccine worth drawing to your attention:

- Recommendation for two dose administration among children who have not previously received pandemic vaccine extends to 9 years of age <u>inclusive</u>. This differs from seasonal vaccine for which two dose recommendation for otherwise unprimed children extends only up to 8 years of age inclusive.
- 2. The interval for second dose administration among those requiring it may be as short as three weeks whereas for seasonal influenza vaccine minimum interval specified is four weeks.

Please remove and destroy the following page from the Communicable Disease Control Manual, Chapter 2 – Immunization Program, Section VII Biological Products:

Page 30c

Dated November 27, 2009

Please insert the following page in the Communicable Disease Control Manual, Chapter 2 – Immunization Program, Section VII Biological Products:

Page 30c

Dated June 2010

If you have any questions or concerns, please contact Karen Pielak, Nurse Epidemiologist, or Cheryl McIntyre, Associate Nurse Epidemiologist, at telephone (604) 707-2510, fax (604) 707-2516 or by email at karen.pielak@bccdc.ca or cheryl.mcintyre@bccdc.ca

Sincerely,

Dr. Monika Naus,

Medical Director, Immunization Program and Associate Medical Director, Epidemiology Services

BC Centre for Disease Control

Kairly leans

pc: Ministry of Healthy Living and Sport:

Dr. Perry Kendall

Dr. Eric Young Deputy Provincial Health Officer Provincial Health Officer

Dr. Bob Fisk Craig Thompson

Medical Consultant Director, CD Prevention – Immunization

Non-Communicable Disease

Warren O'Briain **Executive Director**

Communicable Disease and Addiction Prevention